Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

• Status: Not yet recruiting
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with T2DM.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Carmot Therapeutics, Inc.
• Collaborator: Carmot Australia First Pty Ltd

Criteria

Inclusion Criteria:

• Participants 18-65 years old, inclusive

• BMI of 25 - 40, inclusive

• Stable body weight for two months

Exclusion Criteria:

• History of significant medical conditions and malignancy

• Uncontrollable hypertension

• History of alcoholism or drug addiction within 1 year prior to Screening

• Current or recent participation in an investigational clinical trial